Traditional RNA design starts from biology that is assumed rather than understood, and proceeds by trial and error. RNA-Logix™ discovers and characterizes the biology in house, then generates, ranks and validates designs against Therna’s own data, recursively.
Platform
Home »
RNA-Logix™ is an AI RNA Biologist that unlocks new biology and designs novel medicines
Two sides of the same strand: mRNA as medicine, mRNA as target
CONTEXT
RNA is studied in relation
to its environment
THERNA
MULTI-LAYERED DATA
Proprietary experimental data
generated to feed models
THERNA
FOUNDATION
BIOLOGY AI
Stackable predictive models built to
address unique aspects of RNA biology
THERNA
GENERATIVE AI FOR
RNA MEDICINE
Generative Al models for mRNA
design and target selection
OUTPUT
Testing and validation of our
De nevo designs
The Only AI Platform Desgined for Both mRNA and ASO / siRNA Therapeutics
CONTEXT
RHA is studied in relation
to its environment
THERNA
MULTI-LAYERED DATA
Proprietary experimental data
generated to feed models
THERNA
FOUNDATION
BIOLOGY AI
Stackable predictive models built to
address unique aspects of RNA biology
THERNA
GENERATIVE AI FOR
RNA MEDICINE
Generative Al models for mRNA
design and Target Selection
OUTPUT
Testing and validation of our
de nevo designs
RNA-Logix™ Platform Capabilities
Discovers and characterizes the biology in house
Tests its own hypotheses against proprietary data, without a new experiment each cycle
The biology and a lab-validated candidate together in about a year
Every program feeds the platform that makes the next one faster
Programmable control of RNA behavior across modalities and diseases
The T-Series Models
mRNA
Therna’s T-Series models are trained on the proprietary data generated by Chronos to understand how mRNA sequence design influences translation, stability, immune response, and tissue and cell specificity. These models enable precise control over coding sequence optimization, allowing mRNA therapeutics to be precisely engineered for predictable and durable performance.
ASOs and siRNA
For antisense oligonucleotides (ASOs) and siRNA, Therna’s models identify optimal target sites and sequence features that drive effective silencing, upregulation, and fine-tuning of genes. By learning directly from functional RNA data, the platform supports rational design of ASO and siRNA therapies with improved potency, specificity, and consistency.
The Recursive Loop
RNA-Logix™ designs, reasons through the biology, tests its own hypotheses against Therna’s proprietary data, and refines until a hypothesis holds. Because the Company generated that data itself, most of this loop runs without a new experiment, so the candidates that reach the bench are already far more refined than in conventional lab-in-the-loop approaches. What reaches the bench is validated in primary cells and in relevant in vivo preclinical models, and those results return to the models. Each program makes the next one faster.
RNA-Logix™ Platform
Understanding
RNA Medicines
Therna uses its proprietary RNA-Logix™ platform to design across the full spectrum of RNA medicines. Each modality offers a different way to influence biology.
Modality 01
mRNA
Messenger RNA carries instructions that direct cells to make a specific protein. It can be used to restore or boost a beneficial protein the body needs.
Modality 02
ASOs
Antisense oligonucleotides are short, single-stranded sequences that bind a target RNA to adjust how a gene is expressed, including dialing a protein down or, in Therna's differentiated approach, switching it up.
Modality 03
siRNAs
Small interfering RNAs are short, double-stranded sequences that selectively silence a target gene to reduce the production of a disease-causing protein.
Because ASOs and siRNAs act with high precision, they can reach disease drivers conventional drugs can't. By first unlocking the underlying biology, RNA-Logix™ learns where and how to intervene, then designs potential new medicines across all three modalities: mRNA, ASOs, and siRNAs.
